Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.52 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.47 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | YES1 | P07947 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.47 |
| ▸ | FER | P16591 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498098 | 0.93 | SYK (0.52) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6505192 | 0.92 | SYK (0.51) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6640603 | 0.82 | SYK (0.55) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6497591 | 0.81 | KDM4E (0.45) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6508112 | 0.81 | SYK (0.65) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6505524 | 0.81 | MAP4K2 (0.76) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6495254 | 0.81 | MAP4K2 (0.77) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6497718 | 0.78 | SYK (0.43) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6496237 | 0.75 | SYK (0.52) | SYKMAP4K2KDRJAK2MAP4K4 | |
| SCHEMBL6499723 | 0.73 | SYK (0.65) | SYKMAP4K2KDRJAK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911443-B2 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-28 | — | — | US | claimed |
| EP-1278750-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-04 | — | — | EP | claimed |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | claimed |
| EP-1278750-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001083485-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | WO | claimed |
| US-6911443-B2 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-28 | — | — | US | disclosed |
| EP-1278750-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | disclosed |
| EP-1278750-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083485-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | XRCC6, XRN2, HRH2 | SYK 1025/4885MAP4K2 2126/4885KDR 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.